StockUS listing USIDYANASDAQHealthcareEarnings Deterioration

Ideaya Biosciences Inc(IDYA) Stock Analysis | Healthcare

USD --+0.00%
Reward56Moderate
Risk20Low
75%Data
Revenue down 95% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 2.47Bn
Reward Ratingⓘ56 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ20 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on IDYA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Ideaya Biosciences Inc?

, a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

AI Brief Pro

The brief on Ideaya Biosciences Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Ideaya Biosciences Inc?

, a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.47B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (56)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.082
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
226,338 shares
$985k
0
3-6months
19,550 shares
$382k
0
6-9months
0
150,000 shares
$1.6M
9-12months
0
0